VTX:NOVN - Novartis Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started Previous CloseCHF 78.36Today's RangeCHF 77.72 - CHF 78.5052-Week RangeCHF 72.45 - CHF 88.30Volume11.21 million shsAverage Volume5.98 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina. Receive NOVN News and Ratings via Email Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange VTX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolVTX:NOVN Previous Symbol CUSIPN/A Webwww.novartis.com Phone+41-61-3241111 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous EmployeesN/A Outstanding SharesN/AMarket Cap$0.00 OptionableNot Optionable Novartis (VTX:NOVN) Frequently Asked Questions What is Novartis' stock symbol? Novartis trades on the VTX under the ticker symbol "NOVN." What price target have analysts set for NOVN? 20 Wall Street analysts have issued 12-month price targets for Novartis' stock. Their forecasts range from CHF 75 to CHF 110. On average, they expect Novartis' stock price to reach CHF 91.30 in the next year. View Analyst Price Targets for Novartis. What is the consensus analysts' recommendation for Novartis? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 1 sell rating, 10 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis. Has Novartis been receiving favorable news coverage? News headlines about NOVN stock have been trending somewhat negative on Friday, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novartis earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the company's share price in the near future. Who are some of Novartis' key competitors? Some companies that are related to Novartis include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE), Ampliphi Biosciences (APHB) and Antibe Therapeutics (ATE). Who are Novartis' key executives? Novartis' management team includes the folowing people: Mr. G. Kelly Martin, CEO & Director (Age 59)Dr. Nathan Stasko, Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)Mr. Jeff N. Hunter, Exec. VP, Chief Bus. Officer & Company Sec. (Age 61)Ms. Paula Brown Stafford, Chief Devel. Officer & Director (Age 53)Mr. Andrew Novak, VP & Chief Accounting Officer What is Novartis' official website? The official website for Novartis is https://www.novartis.com/. How can I contact Novartis? Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111. MarketBeat Community Rating for Novartis (VTX NOVN)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 175 (Vote Outperform)Underperform Votes: 218 (Vote Underperform)Total Votes: 393MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: Does the discount rate affect the economy?